MedWatch

Analyst ahead of ALK report: Focus will be on 2022 prognosis

Allergy company ALK will showcase relatively high R&D costs and will likely also report of increasing marketing expenses in tomorrow’s financial report, says an analyst from Sydbank.

Photo: ALK / PR

Sales growth of ALK’s allergy tablets alongside the 2022 guidance will be center stage tomorrow, when the allergy company publicizes its full-year financial report.

The company has delivered nice organic growth rates in recent years, with 2019 coming to 11 percent and 2020 bringing 8 percent. The newly ended year 2021 is also expected to have landed double-digit organic growth.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs